Clinical trials: AMD - Age-Related Macular Degeneration
Choroidal Neovascularization, Wet Macular Degeneration
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.
- Trial name
- DECO (NCT03452527)
- Testing
- ICON-1, aflibercept
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Iconic Therapeutics, Inc.
Wet Age-related Macular Degeneration
A Long-term Follow up Study of EXG102-031 in Participants With wAMD
This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD.
- Trial name
- NCT06859515
- Testing
- No intervention, only for observational studies
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Guangzhou Jiayin Biotech Ltd
Age - Related Macular Degeneration (AMD)
Effect of Fu's Subcutaneous Needling for Age-related Macular Degeneration
This pilot randomized controlled trial aims to evaluate the efficacy and safety of FSN in improving symptoms in patients with dAMD.38 eligible participants will be recruited and randomly assign them in a 1:1 ratio to the FSN…
- Trial name
- NCT07121127
- Testing
- FSN+Vitamin supplement, Vitamin Supplements
- Volunteers
- 38 people
- Sponsor
- Zhiming Yan
Age-related Macular Degeneration, Choroidal Neovascularization
Imaging of the Angiofibrotic Switch in Neovascular AMD
The content of this research project is to identify the angiofibrotic switch, the transition from angiogenesis to fibrosis, in neovascular age-related macular degeneration (nAMD) longitudinally.
- Trial name
- NCT03838679
- Testing
- Best-corrected Visual acuity testing (BCVA), Optical coherence tomography (OCT), Color fundus photography (CFP)
- Where
- Austria
- Volunteers
- 120 people
- Sponsor
- Medical University of Vienna
Choroidal Neovascularization, Age-Related Macular Degeneration
Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV
This pilot study is designed to evaluate the safety and efficacy of intravitreal ranibizumab used in combination with verteporfin photodynamic therapy (Visudyne®) compared to ranibizumab monotherapy for the treatment of subfoveal…
- Trial name
- NCT00429962
- Testing
- intravitreal ranibizumab, intravitreal ranibizumab & photodynamic therapy
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University Hospital, Basel, Switzerland
Geographic Atrophy, Age-Related Macular Degeneration
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 23 visit on study…
- Trial name
- NCT05536297
- Testing
- avacincaptad pegol
- Where
- 117 sites in United States, Argentina and 15 more
- Volunteers
- 278 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Retinal Disease, Macular Degeneration
Stem Cell Ophthalmology Treatment Study
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease. http://mdstemcells.com/scots-ii/
- Conditions
- Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease
- Trial name
- SCOTS (NCT01920867)
- Testing
- RB (Retrobulbar), ST (Subtenon), IV (Intravenous)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- MD Stem Cells
Macular Degeneration
Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab
TREX is a phase IIIb, multicenter, randomized, controlled clinical study. Subjects will be randomized 1:2 to "monthly" (control arm) or "treat and extend" protocol (comparator arm) respectively.
- Trial name
- T-REX (NCT01748292)
- Testing
- 0.5 mg ranibizumab
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Charles C Wykoff, PhD, MD
Age-Related Macular Degeneration
Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E
The investigator propose to conduct a randomized clinical trial, investigating the safety and efficacy of brolucizumab for treatment of nAMD patients with CNV, and plans to specifically target those who are not responding to…
- Trial name
- NCT05710471
- Testing
- Brolucizumab, Aflibercept
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- The University of Hong Kong
Age Related Macular Degeneration
Comparison Between Foresee Home and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)
The Foresee Home is used in the recent years to detect age-related macular degeneration (AMD) lesions. The device is capable of differentiation as to stages of AMD and early detection of changes including choroidal…
- Trial name
- NCT01073592
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Notal Vision Ltd.
Wet Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD
The purpose of this study is to compare the efficacy and safety of MW02 versus Lucentis in the treatment of neovascular age-related macular degeneration.The study was divided into two stages.
- Trial name
- NCT05297292
- Testing
- MW02, Lucentis
- Where
- China
- Volunteers
- 433 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Geographic Atrophy, Age Related Macular Degeneration
Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
The purpose of this study is to assess the Safety and Efficacy of IONIS-FB-Lrx for up to 120 patients with Geographic Atrophy secondary to Age Related Macular Degeneration
- Trial name
- NCT03446144
- Testing
- IONIS-FB-Lrx
- Where
- 37 sites in United States, Australia and 1 more
- Sponsor
- Ionis Pharmaceuticals, Inc.
Neovascular Age-Related Macular Degeneration
Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration
The purpose of this study is to assess the systemic pharmacokinetics (PK) and safety of 2 different doses of brolucizumab (3 milligrams (mg)/50 microliters (μL) and 6 mg/50 μL) when administered at 4-week intervals for a total of…
- Trial name
- NCT02507388
- Testing
- Brolucizumab 3 mg/50 μL, Brolucizumab 6 mg/50 μL
- Volunteers
- 51 people
- Sponsor
- Alcon Research
Age-related Macular Degeneration
Seven Year Update of Macular Degeneration Patients
The purpose is to assess long term vision outcomes and disease status in patients with age-related macular degeneration previously treated with ranibizumab as participants in the Phase 3 ANCHOR and MARINA Studies and the HORIZON…
- Trial name
- SEVEN UP (NCT01256827)
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- University of California, San Francisco
Macular Degeneration, Choroidal Neovascularization
Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
This study evaluated the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity and anatomic outcomes compared to ranibizumab monotherapy and the durability of response observed in…
- Trial name
- NCT00436553
- Testing
- Verteporfin Photodynamic Therapy, Ranibizumab
- Where
- 43 sites in United States, Canada
- Volunteers
- 321 people
- Sponsor
- Novartis
Cataract, Age Related Macular Degeneration
Cataract and AMD in a Trial of a Multivitamin and Cocoa Extract
COSMOS-Eye is an ancillary study of the COcoa-Supplement and Multivitamins Outcomes Study (COSMOS; NCT02422745). COSMOS is a randomized clinical trial of cocoa extract supplement (containing a total of 500 mg/d flavanols…
- Trial name
- COSMOS-Eye (NCT03205202)
- Testing
- Cocoa extract, Multivitamin
- Volunteers
- 21,442 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Age - Related Macular Degeneration (AMD)
International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study
This study aims to expand the CE mark IFU of the SING IMT™ to pseudophakic (patients with an intraocular lents) patients with late stage of AMD (Age-Related Macular Degeneration) and bilateral central vision impairment.
- Trial name
- PERSPECTIVE (NCT07164378)
- Testing
- Lens-Exchange, Add-on
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 44 people
- Sponsor
- VisionCare, Inc.
Photobiomodulation, Age-Related Macular Degeneration
Photobiomodulation for Dry Age Related Macula Degeneration
The study will investigate the effect of photobiomodulation treatment on the risk of developing late age related macula degeneration (AMD) in the study eye in patients with wet AMD in the fellow eye.
- Trial name
- NCT05507840
- Testing
- Valeda machine
- Volunteers
- 121 people
- Sponsor
- Oslo University Hospital
Neovascular Age-related Macular Degeneration (nAMD)
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients…
- Trial name
- CONSTANCE (NCT06795048)
- Testing
- Faricimab
- Where
- 67 sites in United States, Australia and 10 more
- Volunteers
- 274 people
- Sponsor
- Hoffmann-La Roche
Dry Age-related Macular Degeneration
EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
The purpose of this clinical study was to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration…
- Trial name
- EXPLORE (NCT04437368)
- Testing
- GT005
- Where
- 55 sites in United States, Australia and 6 more
- Volunteers
- 98 people
- Sponsor
- Gyroscope Therapeutics Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.